Orange Foundation - Stranger from Konrad Kidawa on Vimeo.
Wyróżniony spot ramach Papaya Young Directors 2018 dla Fundacji Orange.
Reżyser – Konrad Kidawa
Reżyser castingu – Magdalena Ziółkowska
Producent – Konrad Kidawa
Kierownik produkcji – Natalia Łodygowska, Angelika Biegarczyk
Autor zdjęć – Maciej Kwaśniewski
Scenograf – Magda Kostyra
II Scenograf – Dominik Dardziński
Kostiumy – Lena Firak, Gosia Walendzik
Charakteryzator – Paulina Nowakowska
Operator kamery – Maciej Kwaśniewski
Asystent kamery – Andrzej Sepioł
Operator stedycam – Mateusz Wasążnik
Mistrz oświetlenia – Paweł Chiczewski
Oświetlecze – Artur Nowak, Patryk Tync
Kierownik planu – Jakub Wypler
Dyżurni – Tomasz Konieczny, Jan Kwaśniewski, Maciej Latawiec
Postprodukcja – Coloroffon
Montażysta – Irek Grzyb
Kolorysta – Kasia Żebrowska
On line – Coloroffon
Supervisor vfx – Filip Czernow
Realizator dźwięku – Irena Jakuszewska
Opieka postprodukcyjna – Łukasz Matkowski
Muzyka / Kompozytor – Ewa Sadowska
Wystąpili – Oskar Olszewski, Weronika Wachowska, Srehal Patel
Podziękowania – Agnieszka Pasternak, Katarzyna Kiliś, Piotr Wachowski, Michał Stępień, restauracja Skubana Gęś, Maciek Marszalek All For Movies, Paweł Kwaśniewski, ATM Grupa, Marcin Mikołajczyk, Film Factory, GripKolektyw
Inhibition of lymphangiogenesis impairs antitumour effects of photodynamic therapy and checkpoint inhibitors in mice
Publication date: September 2017
Source:European Journal of Cancer, Volume 83
Author(s): Angelika Muchowicz, Malgorzata Wachowska, Joanna Stachura, Katarzyna Tonecka, Magdalena Gabrysiak, Dominika Wołosz, Zofia Pilch, Witold W. Kilarski, Louis Boon, Tomasz J. Klaus, Jakub Golab
Photodynamic therapy (PDT) has been shown to destroy tumour-associated lymphatic vessels. Therefore, we sought to investigate the functional outcomes of PDT-mediated damage to the lymphatic vessels. We observed that PDT with verteporfin, completely but transiently, blocks the functional lymphatic drainage in the orthotopic mammary tumour models. Sustained inhibition of lymphatic vessels regeneration induced by lenalidomide or the soluble form of vascular endothelial growth factor receptor 3 (sVEGFR3) that neutralises lymphangiogenic vascular endothelial growth factor C (VEGF-C), significantly impaired antitumour efficacy of PDT. Antilymphangiogenic compounds also significantly inhibited the ability of intratumourally inoculated dendritic cells (DCs) to translocate to local lymph nodes and diminished the number of tumour-infiltrating interferon-γ-secreting or tumour antigen-specific CD8+ T cells. Lenalidomide also abrogated antitumour effects of the combination immunotherapy with PDT and anti-programmed death-ligand 1 (PD-L1) antibodies. Altogether, these findings indicate that PDT-mediated damage to the lymphatic vessels negatively affects development of antitumour immunity, and that drugs that impair lymphatic vessel regeneration might not be suitable for the use in combination with PDT.
http://ift.tt/2sP1FeT